10 results match your criteria: "Noujaim Institute for Pharmaceutical Oncology Research[Affiliation]"
IDrugs
December 1999
Noujaim Institute for Pharmaceutical Oncology Research, University of Alberta, Edmonton, Alberta T6G 2N8, Canada.
Functional diagnostic imaging techniques, including planar radioscintography, single photon emission tomography, positron emission tomography and computed magnetic resonance imaging, are universally-accepted procedures in medical diagnosis. This symposium focused on the evolving role of these techniques in the discovery and development of new drugs for human use. The relationships between academic/clinical imaging units and the pharmaceutical industry, were examined and assessed in terms of current drug development collaborations.
View Article and Find Full Text PDFIDrugs
March 2000
Noujaim Institute for Pharmaceutical Oncology Research, University of Alberta, Edmonton, Alberta T6G 2N8, Edmonton, Canada.
The field of drug delivery is moving rapidly from the more efficacious delivery of 'old' drugs, to the delivery of therapeutic peptides, proteins, oligonucleotides and genes. Liposomes, polymers, microbubbles, nanoparticles, wafers and chips are the jargon, and entrepreneurialism is the prevailing force. Indeed, the scientific spirit is overwhelmed by the push to market, as fledgling companies compete or collaborate with the established pharma industry in converting concepts into profits.
View Article and Find Full Text PDFIDrugs
October 2000
The Noujaim Institute for Pharmaceutical Oncology Research, University of Alberta, 3118 Dentistry/Pharmacy Center, Edmonton, AB T6G 2N8, Canada.
Twenty five years ago, monoclonal antibodies were envisioned as magic bullets capable of targeting radioisotopes, toxins or cytotoxic drugs to the tumor site. It was soon realized that the potential of therapeutic antibodies far exceeded their use as carrier molecules and that native antibodies could also act as effector molecules capable of triggering a wide variety of antitumor responses. Today, we recognize that the utility and versatility of antibody-based products are unlimited; at the same time we have also learned that many obstacles need to be addressed to make antibody therapy an effective treatment modality.
View Article and Find Full Text PDFJ Pharm Pharm Sci
February 2005
Faculty of Pharmacy and Pharmaceutical Sciences, Noujaim Institute for Pharmaceutical Oncology Research, University of Alberta, Edmonton, Alberta, Canada.
Purpose: The treatment of late stage ovarian cancer presents an unmet clinical need for women around the world. A multistep radioimmunotherapeutic (RIT) approach, exploiting the combination of a bispecific monoclonal antibody (BsMAb) with 90Y labelled biotinylated long-circulating liposomes was tested as a potential adjuvant treatment for epithelial ovarian carcinomatosis in an attempt to meet this need. This approach was used to overcome some of the major obstacles associated with conventional strategies, in particular, to increase the amount of radioactivity delivered to the tumor site compared with conventional monoclonal antibody (MAb) radionuclide delivery.
View Article and Find Full Text PDFIDrugs
July 2003
Noujaim Institute for Pharmaceutical Oncology Research, University of Alberta, Edmonton, Canada.
Adv Drug Deliv Rev
October 1999
Noujaim Institute for Pharmaceutical Oncology Research, Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, Alberta, Canada
The life cycle of HIV involves nine sequential stages. Of these, the reverse transcription (RT) process is a prime target for drug therapy, using both nucleoside and non-nucleoside inhibitors of RT. There are currently five marketed 2',3'-dideoxynucleoside RT inhibitors, but there is need for drugs with improved therapeutic efficacy, decreased development of resistance and broader spectrum to treat resistant strains.
View Article and Find Full Text PDFNucleosides Nucleotides
August 1999
Noujaim Institute for Pharmaceutical Oncology Research, U. Alberta, Edmonton, Canada.
Selective radiolabelling and imaging of transduced HSV tk expressing cells was studied using [123I]IVFRU, [125I]FIRU and [125I]FIAU. Although all three radionucleosides accumulated in the KBALB-STK transduced murine tumour line in vitro and in vivo, [125I]FIRU provided optimal performance in terms of selectivity for HSV tk expressing cells and % of injected dose accumulating in the tumor.
View Article and Find Full Text PDFAnticancer Drug Des
February 1999
Noujaim Institute for Pharmaceutical Oncology Research, Faculty of Pharmacy and Pharmaceutical Sciences, Edmonton, Alberta, Canada.
Certain DNA minor groove binding agents, distamycin, netropsin, and a series of anticancer bis-benzimidazoles can block DNA helicase activity by binding to duplex DNA at specific base sequences. DNA helicases are crucial to cell DNA replication, transcription and repair because these enzymes separate double-stranded DNA, thereby preparing the strands for enzymatic manipulation. From our studies we have developed a hypothesis that focuses on cellular DNA helicase action as a mechanistic site where these minor groove binders can act.
View Article and Find Full Text PDFQ J Nucl Med
June 1997
Noujaim Institute for Pharmaceutical Oncology Research, University of Alberta, Edmonton, Canada.
Advances in genetic engineering and molecular biology have opened the door to disease treatment by transferring genes to cells that are responsible for the pathological condition being addressed. These genes can serve to supplement or introduce the function of indigenous genes that are either inadequately expressed or that are congenitally absent in the patient. Additionally, however, they can introduce new functions such as drug sensitization, to provide a unique therapeutic target.
View Article and Find Full Text PDFQ J Nucl Med
September 1996
Noujaim Institute for Pharmaceutical Oncology Research, Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, Canada.
Although hypoxia has been known for decades to play an important role in the outcome of radiotherapy in oncology, and inspite of the contribution of hypoxia to a myriad of pathologies that involve vascular disease, the selective imaging of hypoxic tissue has attained prominence only within the past decade. Contemporary research in the hypoxia imaging field is based largely on radiosensitizer research of the 1960's and 1970's. Early sensitizer research identified a family of nitro-organic compounds, the N-1 substituted 2-nitroimidazoles as candidate drugs.
View Article and Find Full Text PDF